NEW BRUNSWICK, N.J., May 12 /PRNewswire-FirstCall/ -- Johnson & Johnson will host a conference call for financial analysts at noon (Eastern Time) on Tuesday, May 19, 2009 to review the primary data from NEVO RES I, the pivotal European trial of the NEVO(TM) Sirolimus-eluting Coronary Stent.
NEVO(TM) is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology. Results from this trial will support a design dossier submission for CE Mark approval in Europe and in other countries that accept CE mark designation.
Seth Fischer, Company Group Chairman, Worldwide Franchise Chairman, Cordis; Campbell Rogers, MD, Chief Scientific Officer and Global Head, R&D, Cordis; and Stan Panasewicz, Director, Investor Relations, Johnson & Johnson, will host the call.
Investors and other interested parties may access the broadcast by visiting the Company’s website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately two hours after the conference call concludes by visiting www.investor.jnj.com.
CONTACT: Media Contact: Christopher Allman, +1-908-541-4807; or Investor
Contacts: Louise Mehrotra, +1-732-524-6491; or Stan Panasewicz,
+1-732-524-2524
Web site: http://www.investor.jnj.com/
